Profile picture

Professor Phil Mc Ewan

Health Economics and Outcomes Research Ltd, Cardiff (United Kingdom of Great Britain & Northern Ireland)
Follow
Biography
Phil is a mathematician who gained his PhD at the School of Mathematics, Cardiff University. His work here involved the development of deterministic and stochastic compartmental simulation models for use with back projection methods for quantifying the incidence of HIV infection. He was then employed as a research associate at the School investigating the use and validity of cardiovascular risk functions in type II diabetes. For twelve years, Phil worked as Director and Senior Research Mathematician at Cardiff Research Consortium. Phil’s technical expertise lies in simulation modelling and multivariate statistical data analysis, whilst his primary academic interest is efficient simulation methods and methods for the reduction of variance in simulation models. Phil is currently Professor and Technical Director at the Centre for Health Economics, Swansea University and Managing Director of HEOR Ltd, working mainly in the area of HIV, oncology, diabetes and infectious disease modelling.
Logo ESC

Contributor content

Assessing the impact of cardiovascular events on health-related quality of life outcomes in DAPA-HF
Presentation
Assessing the impact of cardiovascular events on health-related quality of life outcomes in DAPA-HF
Evaluating the key predictors of health-related quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial
Presentation
Evaluating the key predictors of health-related quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial
AFFIRM-AHF Cost-Effectiveness Modelling Results in 4 Countries (US, UK, CH & IT).
Presentation
AFFIRM-AHF Cost-Effectiveness Modelling Results in 4 Countries (US, UK, CH & IT).
AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting
Presentation
AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting
Budget impact evaluation of the DAPA-HF trial: is dapagliflozin cost-saving for the treatment of heart failure with reduced ejection fraction?
Presentation
Budget impact evaluation of the DAPA-HF trial: is dapagliflozin cost-saving for the treatment of heart failure with reduced ejection fraction?
The relationship between duration of heart failure, serum potassium concentration and adverse clinical outcomes
Presentation
The relationship between duration of heart failure, serum potassium concentration and adverse clinical outcomes
Estimating the burden of hyperkalaemia in the UK in high-risk patient populations
Presentation
Estimating the burden of hyperkalaemia in the UK in high-risk patient populations
Assessing the relationship between serum potassium variability and the risk of hyperkalaemia and adverse clinical outcomes
Presentation
Assessing the relationship between serum potassium variability and the risk of hyperkalaemia and adverse clinical outcomes

ESC 365 is supported by